Orwin John A
- SEC CIK
- 0001477384
No open-market purchases or sales filed in the past year.
Current role at each company
- ANAB Anaptysbio, IncDirectoras of Sep 17, 2026
- TRAX First Tracks Biotherapeutics, Inc.Directoras of Sep 17, 2026
- TVTX Travere Therapeutics, Inc.Directoras of May 21, 2026
- CRGX CARGO Therapeutics, Inc.Directoras of Aug 19, 2025
- BCEL Atreca, Inc.PRESIDENT & CEOas of Apr 17, 2024
Show 1 more company
- SGEN Seagen Inc.Directoras of Dec 15, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Orwin John A as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BCEL Atreca, Inc.
PRESIDENT & CEO3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2024 (view filing)7:36 PM ET | Apr 11 | 6 daysLate | Orwin John APRESIDENT & CEO | PPurchaseSeries A Junior Preferred Stock | +1 | $0.01 | +$0.01 | New position1 after | |
| Apr 3, 2024 (view filing)9:37 PM ET | Sep 1, 2023 | 215 daysLate | Orwin John APRESIDENT & CEO | SSaleClass A Common Stock | −23.0K | $0.3746 | −$8.60K | −22.8%77.5K after | |
| Sep 20, 2022 (view filing) | Sep 2 | 18 daysLate | Orwin John APresident & CEO | SSaleClass A Common Stock | −20.9K | $1.78 | −$37.2K | −17.2%100.5K after |